GSK adds to COPD pipeline as Exscientia deal bears fruitAI drug research firm Exscientia has delivered the first candidate molecule to its partner GlaxoSmithKline following an R&D Share XGSK adds to COPD pipeline as Exscientia deal bears fruithttps://pharmaphorum.com/about-pharmaphorum/gsk-adds-to-copd-pipeline-as-exscientia-deal-bears-fruit/
AI drug R&D firm Exscientia expands into JapanAI drug R&D firm Exscientia has announced it has expanded into Japan, after clinching a major research deal Share XAI drug R&D firm Exscientia expands into Japanhttps://pharmaphorum.com/news/ai-drug-rd-firm-exscientia-expands-into-japan/
AI drug R&D company Exscientia signs deal with CelgeneUK artificial intelligence (AI) drug discovery company Exscientia has agreed a three year drug discovery deal with Celgene, Share XAI drug R&D company Exscientia signs deal with Celgenehttps://pharmaphorum.com/news/ai-drug-rd-company-exscientia-signs-deal-with-celgene/
Exscientia to discuss role of AI in small molecule drug discoveryAI in small molecule drug discovery Share XExscientia to discuss role of AI in small molecule drug discoveryhttps://pharmaphorum.com/partner-content-digital/exscientia-discuss-role-ai-small-molecule-drug-discovery/
